Next generation Fc scaffold for multispecific antibodies
Summary: Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle...
Guardado en:
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/daec344ee874422b8d613ca7fb390ad7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:daec344ee874422b8d613ca7fb390ad7 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:daec344ee874422b8d613ca7fb390ad72021-11-28T04:36:35ZNext generation Fc scaffold for multispecific antibodies2589-004210.1016/j.isci.2021.103447https://doaj.org/article/daec344ee874422b8d613ca7fb390ad72021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589004221014188https://doaj.org/toc/2589-0042Summary: Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3′ interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies.Bram EstesAthena SudomDanyang GongDouglas A. WhittingtonVivian LiChristopher MohrDanqing LiTimothy P. RileyStone D.-H. ShiJun ZhangFernando GarcesZhulun WangElsevierarticleBiochemistryBioengineeringBiomolecular engineeringStructural biologyScienceQENiScience, Vol 24, Iss 12, Pp 103447- (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Biochemistry Bioengineering Biomolecular engineering Structural biology Science Q |
spellingShingle |
Biochemistry Bioengineering Biomolecular engineering Structural biology Science Q Bram Estes Athena Sudom Danyang Gong Douglas A. Whittington Vivian Li Christopher Mohr Danqing Li Timothy P. Riley Stone D.-H. Shi Jun Zhang Fernando Garces Zhulun Wang Next generation Fc scaffold for multispecific antibodies |
description |
Summary: Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3′ interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies. |
format |
article |
author |
Bram Estes Athena Sudom Danyang Gong Douglas A. Whittington Vivian Li Christopher Mohr Danqing Li Timothy P. Riley Stone D.-H. Shi Jun Zhang Fernando Garces Zhulun Wang |
author_facet |
Bram Estes Athena Sudom Danyang Gong Douglas A. Whittington Vivian Li Christopher Mohr Danqing Li Timothy P. Riley Stone D.-H. Shi Jun Zhang Fernando Garces Zhulun Wang |
author_sort |
Bram Estes |
title |
Next generation Fc scaffold for multispecific antibodies |
title_short |
Next generation Fc scaffold for multispecific antibodies |
title_full |
Next generation Fc scaffold for multispecific antibodies |
title_fullStr |
Next generation Fc scaffold for multispecific antibodies |
title_full_unstemmed |
Next generation Fc scaffold for multispecific antibodies |
title_sort |
next generation fc scaffold for multispecific antibodies |
publisher |
Elsevier |
publishDate |
2021 |
url |
https://doaj.org/article/daec344ee874422b8d613ca7fb390ad7 |
work_keys_str_mv |
AT bramestes nextgenerationfcscaffoldformultispecificantibodies AT athenasudom nextgenerationfcscaffoldformultispecificantibodies AT danyanggong nextgenerationfcscaffoldformultispecificantibodies AT douglasawhittington nextgenerationfcscaffoldformultispecificantibodies AT vivianli nextgenerationfcscaffoldformultispecificantibodies AT christophermohr nextgenerationfcscaffoldformultispecificantibodies AT danqingli nextgenerationfcscaffoldformultispecificantibodies AT timothypriley nextgenerationfcscaffoldformultispecificantibodies AT stonedhshi nextgenerationfcscaffoldformultispecificantibodies AT junzhang nextgenerationfcscaffoldformultispecificantibodies AT fernandogarces nextgenerationfcscaffoldformultispecificantibodies AT zhulunwang nextgenerationfcscaffoldformultispecificantibodies |
_version_ |
1718408287974588416 |